Saint-Herblain, France – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children, twelve months after vaccination....
Latest News
GRAND RAPIDS, Mich. (April 16, 2024) — A new study from Van Andel Institute scientists offers a first look into the complex molecular changes that occur in brain cells with Lewy bodies, which are key pathological hallmarks of Parkinson’s disease and some dementias. The findings, published in the journal Nature Communications, reveal...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). VCA-894A is being developed for a patient who was...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial” in the Clinical Gastroenterology and Hepatology Journal which follows a previously published study of tradipitant in the treatment...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV). PV is a chronic myeloproliferative disorder characterized by aberrant hematopoiesis of myeloid lineage...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study” in the Journal of Clinical Psychiatry. The findings of this pivotal study have been submitted to the U.S. Food and Drug Administration (FDA) as...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene. CMT2S...
Nashville, TN – By mapping the cellular and molecular geography of colorectal cancer, Vanderbilt University and Vanderbilt University Medical Center researchers collaboratively have discovered why most colorectal tumors escape detection and destruction by the body’s immune system. Their findings, reported in the journal Cell, could lead to new ways to...